ivWatch Intellectual Property Grows with Three International Patents

Latest patent grants cover core product technologies

HAMPTON, Va., February 8, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of peripheral intravenous (PIV) infiltrations and extravasations, recently had three patent applications granted by the Japanese and Australian Patent Offices expanding the company’s intellectual property portfolio.

“Today’s healthcare marketplace is growing increasingly competitive with the introduction of new devices and technologies, so we must continue to build on our successes in this space by protecting our innovations,” said Gary Warren, president and CEO of ivWatch. “Our philosophy regarding intellectual property is to aggressively protect our proprietary technology to expand our product portfolio and develop licensing opportunities with strategic partners.”

Granted Japanese Patent Application No. 2015-553708 is for a core technology regarding the geometry of ivWatch sensor heads – for both the fiber optic and electronic systems – which has secured ivWatch’s position as a first, and only, technology of its kind in the market. Optimal light angles and distances of the various sensor parts allow the technology to detect infiltrations with high sensitivity to aid healthcare providers in an early diagnosis of these most serious events during intravenous (IV) therapy.

Granted Japanese Patent Application No. 2015-510267 is for a second core technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, more commonly known as receptacles, may be independent of the dressings that cover infusion sites during IV therapy or may be integrated with those dressings. The granting of these applications comes just months after ivWatch entered into a licensing and distribution agreement with Terumo Corporation helping to advance patient safety in Japan and on a global scale.

Australian Patent No. 2013316021 is directed to a third core technology for mitigating the effects of tissue blood volume changes. The Australian patent corresponds to U.S. Patent No. 9,326,686, for solving motion issues related to continuous PIV therapy monitoring. The patent is directly related to the ability of the ivWatch Model 400 to reduce the number of “false” notifications helping combat an epidemic of clinicians becoming desensitized to alarms, many of which are false or clinically irrelevant.

These new grants are in addition to the two patents already in ivWatch’s intellectual property portfolio, which also includes numerous utility patent applications. This portfolio gives ivWatch the right to prevent others from making, using or selling our products in the U.S. and major international markets.

There is a rapid demand for breakthrough technology as more healthcare facilities focus on value-based care to lower costs and improve patient safety and satisfaction. IV infiltration and extravasation is a major problem as it can lead to serious medical complications and even amputation. The ivWatch Model 400 continuously monitors a patient’s PIV for evidence of infiltrations and extravasations, which occur when medication or fluid leaks into the surrounding tissue. Early detection of those failures via ivWatch biosensor technology helps to minimize injuries associated with this common complication of IV therapy.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivWatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Awarded Breakthrough Technology Agreement with Premier

HAMPTON, Va.., February 6, 2018 – ivWatch, LLC has been awarded a group purchasing agreement as a Breakthrough Technology with Premier. Effective Feb.1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the ivWatch Model 400, a continuous monitoring device for the early detection of peripheral IV (PIV) infiltrations.

“We are thrilled to be recognized by Premier as a Breakthrough Technology which accelerates the standard GPO process and enables us to educate more organizations about our technology offering a new standard of care for PIVs,” said Scott Hensley, vice president of sales and business development at ivWatch. “This recognition is a testament to the need for a technology solution in hospitals for continuous IV monitoring for early detection of IV infiltrations and extravasations.”

This relationship enables Premier members to implement continuous monitoring of a patient’s PIV for evidence of infiltrations to improve patient outcomes. Intravenous therapy is a routine part of treatment for nearly 80 percent of patients in the U.S., yet more than 20 percent of these IVs may fail due to infiltration, risking both a serious drug delivery error and tissue damage. The ivWatch sensor technology is a solution to aid the clinician in early detection of this most serious event.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivwatch.com/

myIV.com Educates Patients on IV Therapy


First website of its kind provides information and tips on ‘all things IV, simplified’ to inform and empower patients and their family members to be their own healthcare advocates

Hampton, VA – January 23, 2018 – Today marks the start of the #myIVawareness campaign with the official launch of myIV.com, a new resource to empower and inform patients and family members responsible for care on intravenous (IV) therapy. myIV.com, sponsored by ivWatch, is the first online patient resource of its kind providing visitors simplified information about IVs and the symptoms of possible complications.

Nearly 80 percent of all hospital patients receive an IV1, making it the most common invasive medical procedure. Still, close to 50 percent of IVs fail due to complications. Every failure of an IV results in a drug delivery error and carries the potential for reduced drug efficacy and physical harm. Complications range from skin redness, burning, tissue necrosis, limb amputation and even death.

“To have a single location with reliable and relevant information on IVs is filling a large gap in patient education,” said Susan Brown, MSN, RN, Med, VA–BC. “I spent many years educating patients and their families on what an IV was, why it was needed and complication symptoms. To have a site for patients to reference before and during a hospital stay will help facilitate better conversations with healthcare professionals.”

Users of the site have free access to comprehensive educational content including a guide on how to talk to your healthcare professional, definitions of common medical terms, IV FAQs, as well as patient stories.

Caitlin King, myIV.com’s first “Patient Spotlight,” wishes she had access to an IV awareness website when one of her twin daughters experienced IV issues shortly after being born seven weeks premature. King hopes other parents take from her experience the importance of educating themselves when it comes to children and IVs.

“There is no awareness about IVs, it’s not talked about, and yet it happens every day,” said King. “As a parent, helplessness is one of the worst feelings in the world. If there is something you can do when it comes to knowing what to look for, do it.”

To learn more about myIV.com and #myIVawareness, visit www.myIV.com and follow myIV.com on Facebook, Twitter, LinkedIn and Pinterest.

1. Zhang, L., Cao, S., Marsh, N., Ray-Barruel, G., Flynn, J., Larsen, E. and Rickard, C.M. (2016) Infection risks associated with peripheral vascular catheters. Journal of Infection Prevention. 17(5), p.207-213. doi: 10.1177/1757177416655472

About myIV.com
myIV.com is an online patient resource portal dedicated to empowering patients with information related to receiving an IV. As the first website of its kind focused on IVs and IV therapy, myIV.com fills the gap in patient education and makes IVs easier to understand. myIV.com is sponsored by ivWatch. Help raise #myIVawareness on Twitter, Facebook, LinkedIn and Pinterest. For more information, visit www.myIV.com.

###

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Office (757) 224-2606, Mobile (757) 660-4949

Gary Warren Named Small Business Champion of the Year Finalist

December 14, 2017 – ivWatch announces Gary Warren, President and CEO of ivWatch is among five small business owners competing for the Hatch “Small Business Champion of the Year” award. The winner receiving the most votes will be named and recognized at the fourth annual State of the Startup Community Address on January 25. Voting is simple and open to anyone now through Sunday, Jan. 21 here.

Under Warren’s leadership, ivWatch is on a pursuit to provide affordable and innovative technology allowing hospitals to improve the safety for their patients by reducing the risks associated with IV infiltration.

“Building a medical device company is both a business risk and costlier than most would realize. And it has been an exciting journey to see the growth of ivWatch over the past eight years,” says Warren. “Our employees are united by the common mission to advance patient safety and it’s rewarding to be at a stage where our product is at work in hospitals across the country.”

The State of the Startup Community Address is organized for the Hampton Roads business community to come together and reflect on progress throughout the year. Hampton-based ivWatch may be small with just under 40 employees, but the prospects are promising as personnel has more than doubled in two years. The company has a dedicated executive team and with increased research and development, sales force and marketing teams they are prepared for continued growth and expansion.

“The five finalists all embody the entrepreneurial spirit of our growing small business community,” says Zack Miller, founder of Hatch. “Gary’s a leader in the Hampton Roads business and entrepreneur communities and our members can look to him to see how an idea can become a company, and how passion can make a company competitive and successful.”

To cast a vote for Gary Warren, please visit http://www.startwithhatch.com/ssca/#champ

About Hatch:
Hatch is an award-winning organization that is dedicated to making entrepreneurship a viable option for everyone. Hatch has helped thousands of entrepreneurs start and grow businesses. In addition to providing entrepreneurs with the tools and resources they need individually, Hatch helps cities champion entrepreneurship within their community and prepare for their future economic needs with investments in human capital. Hatch is located in Norfolk, Virginia.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttp://www.ivWatch.com

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

World Pediatric Project adds Gary Warren to Executive Board of Directors

October 25, 2017 – ivWatch announces that Gary Warren, President and CEO of ivWatch, LLC has recently been added to the World Pediatric Project (WPP) Executive Board of Directors. Mr. Warren brings extensive executive experience in developing and managing high-growth technology and venture-backed private companies to the Executive Board.

Mr. Warren and the other members of the WPP Executive Board share a passion for bringing advanced technology to underserved areas. Access to the latest medical devices and technology, combined with the talent and commitment of the WPP volunteer doctors, surgeons, and nurses, allows WPP to help thousands of children each year. As a part of the newly structured executive board, Mr. Warren will help oversee operations and financials of WPP.

“It is an honor to be a part of this well-established organization”, says Gary Warren, ivWatch President & CEO. “My goal is to expand recognition for WPP beyond its current base of supporters. The countries and families served by WPP need access to the type of healthcare and surgery we expect and see as ‘basic’ here in the United States. This access could not be more immediate in many areas WPP serves due to the recent destruction caused by hurricanes and flooding.”

ivWatch supported a surgical mission to St. Vincent and the Grenadines in 2016. The company was able to send a number of its medical devices to be used during and after surgery. The ivWatch Model 400 is a continuous monitoring system that allows clinicians to better manage the risk of IVs by providing early detection of infiltration and extravasation, when fluid leaks outside of the vein.

“We are thrilled to have Gary join our Executive Board of Directors,” says Susan Rickman, CEO of World Pediatric Project. “It’s an exciting time for our organization as we launch and begin to roll out our most recent strategic initiative, Transformation2023. Gary’s experience and insight will help us achieve our goal of healing more children, sooner.”

World Pediatric Project’s Tranformation2023 includes:

  • Accelerating WPP’s effective outreach twice as fast with 3,000 or more children helped 7 years sooner
  • Cumulatively reaching 13,000 children benefiting from 36,000 procedures within 7 years
  • Financial contributions of $45 million delivering $206 million in pediatric specialist care

For more information on World Pediatric Project or to donate, please visit: https://www.worldpediatricproject.org/

About World Pediatric Project
World Pediatric Project is a 501(c)(3) nonprofit organization dedicated to healing critically ill children and building healthcare capacity in the world. Founded in 2001, WPP mobilizes pediatric diagnostic and surgical teams to low resource countries in the Caribbean and Central America and brings children to partner hospitals in the United States for care. For more information, visit worldpediatricproject.org or call 804-282-8830. Like us on Facebook and follow us on Twitter.

MEDIA CONTACT: Jason Kenney, jkenney@worldpediatricproject.org, Office (804)-282-8830

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLC. https://www.ivwatch.com/

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Enters into Licensing and Distribution Agreement with Terumo to Help Improve Patient Safety

Terumo Corporation named exclusive distributor for ivWatch in Japan, licenses ivWatch continuous IV infiltration detection technology for use in its products globally.

September 21, 2017 – HAMPTON, VA – ivWatch, LLC, the market leader for continuous IV infiltration and extravasation detection technology, today announced that Terumo Corporation, one of the world’s leading medical device manufacturers and distributors, is the exclusive distributor of the ivWatch Model 400 and the ivWatch OEM board in Japan, and is a global licensing partner for Terumo products containing the ivWatch OEM board.**

“We have partnered with ivWatch because they offer the most advanced technology to help minimize patient harm through the early detection of IV infiltration events,” said Tsuyoshi Tomita, group manager, General Hospital Products Group, General Hospital Company at Terumo Corporation. “We are confident that the ivWatch technology will help hospitals improve patient safety by reducing the harm caused by IV infiltration.”

IV therapy is the most common invasive hospital procedure worldwide. A recent study, conducted at a university hospital in Tokyo, Japan, found that catheters failed at a rate of 18.8 percent with 41.3 percent of those failures due to infiltration.(1) Every failure of an IV results in a drug delivery error and carries the potential for reduced drug efficacy and physical harm.

“We are excited to partner with Terumo to help advance patient safety in Japan and on a global scale,” said Gary P. Warren, president and CEO of ivWatch, LLC. “Through the distribution of the ivWatch Model 400 and future integration of the ivWatch OEM board with Terumo products, Terumo will be able to help their customers deliver a higher level of patient care and reduced risks related to IV therapy. This partnership furthers our collective goal of ending the harm associated with IV infiltration and extravasation.”

IV infiltration and extravasation is a major problem as it can lead to serious medical complications and even amputation. The ivWatch Model 400 continuously monitors a patient’s peripheral IV for evidence of infiltrations and extravasations, which occur when medication or fluid leaks into the surrounding tissue. Early detection of those failures via ivWatch sensor technology helps to minimize injuries associated with this common complication of IV therapy.

ivWatch technology can be seamlessly integrated with patient monitoring systems, infusion pumps and other devices via the ivWatch OEM board. The agreement provides Terumo with exclusive rights to integrate ivWatch into existing and future Terumo products in Japan. In addition, Terumo can integrate ivWatch technology into products available globally.

About Terumo:
Tokyo-based Terumo Corporation is one of the world’s leading medical device manufacturers with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation’s shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol , or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan’s leading stock index.

Terumo Corporation – 2-44-1 Hatagaya, Shibuya-ku, Tokyo, Japan. http://www.terumo.com

About ivWatch:
ivWatch, LLC is a medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. ivWatch provides a first-of-its-kind, FDA-cleared, noninvasive medical device that continuously monitors peripheral IVs for infiltration and extravasation events. The ivWatch Model 400 aims to help eliminate patient harm associated with adverse events and to reduce drug delivery errors. The ivWatch OEM Board integrates ivWatch technology into existing products, enabling OEMs to help healthcare providers deliver a higher level of patient care and to reduce risks related to IV therapy.

The ivWatch OEM Board is not an FDA-cleared device. It is the responsibility of the Original Equipment Manufacturer integrating ivWatch technology to secure the proper regulatory clearance. Follow us on Twitter@ivWatch or Facebook @ivWatchLLC. www.ivWatch.com

MEDIA CONTACT: Leah Moore, leah.moore@ivwatch.com, Office (855) 489-2824 x7031, Mobile (757) 839-5653

**The ivWatch OEM Board integration and ivWatch Model 400 will be available internationally pending the necessary regulatory approvals.

(1) J Infus Nurs. 2017 Jul/Aug;40(4):224-231. doi: 10.1097/NAN.0000000000000168.

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest